Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07244380 | Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | not yet recruiting | Phase 2 | 38 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07018310 | Micro Assays for HemATology Malignancies Antibody Treatment(MAHATMAt) | not yet recruiting | N/A | 166 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 20, 2025 |
| clinicaltrials |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 40 | Li ZhimingOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07233018 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 24 | MEI HENGOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | not yet recruiting | Phase 2 | 27 | University Hospital TuebingenOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07210749 | Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma | not yet recruiting | N/A | 36 | British Columbia Cancer AgencyOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma(FIL_PUMA) | not yet recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07209163 | Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Ruijin HospitalOTHER | 0 | Oct 6, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07200882 | What is the Impact of TKI on Thyroid Function in CML Patients? | not yet recruiting | — | 76 | Assiut UniversityOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198373 | Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma | not yet recruiting | — | 40 | Beijing GoBroad HospitalOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT07198464 | Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma | not yet recruiting | N/A | 30 | Zhengzhou UniversityOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 228 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma(QLS32015) | not yet recruiting | Early Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06281847 | An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia(RESOLVE AML001) | not yet recruiting | Phase 1 / Phase 2 | 143 | Advesya SASINDUSTRY | 4 | Sep 18, 2025 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Early Phase 1 | 3 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07178457 | Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance(BeCALM) | not yet recruiting | Phase 3 | 84 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07179094 | The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash | not yet recruiting | N/A | 72 | Şule GüzleOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07175415 | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART E) | not yet recruiting | Phase 1 / Phase 2 | 42 | Princess Maxima Center for Pediatric OncologyOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07045168 | Risk-adapted Therapeutic Strategy in +1q NDMM | not yet recruiting | — | 200 | FengYan JinOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07169565 | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia | not yet recruiting | Phase 1 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 11, 2025 | clinicaltrials |
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | not yet recruiting | Phase 2 / Phase 3 | 306 | Actinium PharmaceuticalsINDUSTRY | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07162532 | Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients | not yet recruiting | — | 45 | Assiut UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07162571 | This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.(MSTH-CAR002) | not yet recruiting | Phase 1 / Phase 2 | 17 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 62 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07157579 | Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient | not yet recruiting | — | 80 | Sohag UniversityOTHER | 0 | Sep 5, 2025 | clinicaltrials |
| NCT07158294 | Identification of BCR::ABL1 Mutations by Digital PCR in CML(DiP-in-CML) | not yet recruiting | N/A | 150 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Sep 5, 2025 | clinicaltrials |
| NCT07150676 | Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Myeloid Leukemia(DOREMy) | not yet recruiting | — | 2,000 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT07145359 | Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation | not yet recruiting | N/A | 30 | Halic UniversityOTHER | 0 | Aug 28, 2025 | clinicaltrials |
| NCT07146542 | Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia | not yet recruiting | — | 66 | Assiut UniversityOTHER | 0 | Aug 28, 2025 | clinicaltrials |
| NCT07143877 | Prognostic Impacts of Lipid Profile and BMI in Adult AML(AML/BMI) | not yet recruiting | — | 200 | Assiut UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07144657 | Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma(GastricMALToma) | not yet recruiting | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07139353 | Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT07035379 | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL | not yet recruiting | Phase 1 / Phase 2 | 66 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07131085 | QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 20, 2025 | clinicaltrials |
| NCT07131449 | Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies(succinylation) | not yet recruiting | — | 200 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT04464603 | Impact of a mHealth Supportive Tool on Cardiopulmonary Resuscitation' Situational Awareness(InterFACE) | not yet recruiting | N/A | 36 | Pediatric Clinical Research PlatformOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07113730 | The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes | not yet recruiting | — | 300 | Peking University People's HospitalOTHER | 0 | Aug 15, 2025 | clinicaltrials |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 0 | Aug 14, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07120607 | Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07117175 | A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy | not yet recruiting | Early Phase 1 | 18 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07117305 | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 1 / Phase 2 | 38 | Zhengzhou UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2025source: clinicaltrials